Sulfosuccinimidyl oleate (Sulfo-N-succinimidyl oleate) 是一种长链脂肪酸，可抑制脂肪酸运输到细胞。Sulfosuccinimidyl oleate 是一种有效且不可逆的线粒体呼吸链抑制剂。Sulfosuccinimidyl oleate 与小胶质细胞表面上的CD36受体结合，具有抗炎效果。

Sulfosuccinimidyl oleate (Sulfo-N-succinimidyl oleate) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate is a potent and irreversible inhibitor of mitochondrial respiratory chain. Sulfosuccinimidyl oleate binds the CD36 receptor on the surface of microglia. Sulfosuccinimidyl oleate is neuroprotective and alleviates stroke-induced neuroinflammation [1] [2].

Sulfosuccinimidyl oleate (20 μM and 50 μM, 24 hours) alone does not change the cellular viability. Exposure to 100 ng/ml LPS+5 ng/mL IFNγ modestly, yet significantly decreases the viability of the BV2 cells. Co-treatment with Sulfosuccinimidyl oleate prevents the LPS+IFNγ-induced reduction in the cell viability [1]. Sulfosuccinimidyl oleate (50 μM, 24 hours) co-treatment significantly reduces the LPS+IFNγ-induced expression of NOS2 and COX-2 in BV2 cells. Western blot analysis reveals a significant LPS/IFNγ-induced upregulation in the phosphorylated form of the p38, which is prevented by co-treatment with Sulfosuccinimidyl oleate (50 μM, 24 hours) [1]. Cell Viability Assay [1] Cell Line: BV2 cells Concentration: 20 μM and 50 μM Incubation Time: 24 hours Result: Did not alter the viability of BV2 cells alone. Exposure of BV2 cells to 100 ng/mL LPS and 5 ng/mL IFNγ significantly reduced the viability of BV2 cells while simultaneous treatment with Sulfosuccinimidyl oleate prevented it. Western Blot Analysis [1] Cell Line: BV2 cells Concentration: 50 μM Incubation Time: 24 hours Result: Drastically increased the levels of NOS2, COX-2, and P-p38/T-p38.

Sulfosuccinimidyl oleate (50 mg/kg; administered once by single oral gavage) significantly reduces the cortical ischemic infarct size compared to vehicle-treated controls in male BALB/cABom mice with pMCAo model. Moreover, Sulfosuccinimidyl oleate at 50 mg/kg is suitable to see a beneficial effect after stroke [1]. Animal Model: 4-month-old male BALB/cABom mice with pMCAo model [1] Dosage: 50 mg/kg Administration: Administered once by single oral gavage Result: Reduced brain damage following ischemia. Attenuated infarct size.

135661-44-8

C22H37NO7S

459.6

Sulfo-N-succinimidyl oleate

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years